Clinical trial · Interventional
SafeHeal Anastomosis Feasibility Evaluation (SAFE)-2023 Study
SafeHeal Anastomosis Feasibility Evaluation (SAFE)-2023 Study: A Study to Investigate the Performance and Safety of the Colovac 2 Colorectal Anastomosis Protection Device
NCT06540807CI-TRIAL-00112119completedN/AResults postedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
A feasibility study to assess the early safety and effectiveness of the Colovac 2 device in providing temporary protection of the anastomosis in patients undergoing low anterior resection for colon cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Colorectal Cancer | Malignant Colorectal Neoplasm | CURATED_BROADER | 0.80 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Colovac Colorectal Anastomosis Protection Device | Device | — | UNRESOLVED |
| Stoma creation | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Colovac
- description
- The Colovac device will be implanted for approximately 10 days.
- interventionNames
- Device: Colovac Colorectal Anastomosis Protection Device
- Procedure: Stoma creation
Primary outcomes (1)
- measure
- Migration
- timeFrame
- 10 days
- description
- Rate of clinically significant device migration The rate of subjects for which the device has migrated clinically significant during its 10-day implant period.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * 18 years of age or older * Eligible to undergo open or minimally invasive sphincter-sparing low anterior resection with planned diverting loop ileostomy for malignancy, based on multidisciplinary team recommendations * Eastern Cooperative Oncology Group (ECOG) Performance Status ≤ 2History of left sided colitis * Willingness to comply with protocol-specific treatment and study visits and to sign a written Informed Consent Form Exclusion Criteria: * History of left sided colitis * Known allergy to nickel or other components of the Colovac 2 System * Pregnant or nursing female subject * Concomitant major surgical procedure in combination with Colorectal resection (i.e., hepatectomy) * Any serious or uncontrolled medical disorder that, in the opinion of the investigator, may increase the risk associated with study participation, impair the ability of the participant to undergo protocol described procedures or interfere with the interpretation of study results including, but not limited to: * Stage IV colorectal cancer unless curative intent R0 resection is planned AND there is no associated peritoneal disease * Immunodeficiency (CD4+ count \< 500 CU MM) * Systemic steroid therapy within the past 6 months * Systemic infection at the time of surgery or requiring systemic antimicrobial therapy up to 1 week before surgery * Major surgical or interventional procedures within 30 days prior to this study or planned surgical or interventional procedures within 30 days of entry into this study * Diagnosis of bowel obstruction, bowel strangulation, peritonitis, bowel perforation, intraabdominal infection, ischemic bowel, carcinomatosis * Fecal incontinence, involvement of sphincter by the neoplastic disease or evidence of extensive local disease in the pelvis seen on pre-operative imaging * Severe malnutrition which is defined as at least 10% weight loss within 3 months prior to enrollment. * Occurrence of any of the following during the colorectal surgery: 1. Blood loss (\>750 cc) 2. Blood transfusion 3. Any new sign of ischemia 4. Positive air leak test 5. Inadequate bowel preparation 6. Anastomosis location greater than 15 cm from the anal verge 7. Other intra-operative risks that preclude the subject from undergoing the procedure with the investigational device
References
Publications (1)
pubmedProvenance
- Source
- PubMed (NLM)
- Dataset
- PubMed E-utilities
- Retrieved
- Sep 14, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
Patricia Sylla, Katherine Lam, Niels Komen et al. · Ann Surg · Sep 2, 2026 · PMID 42681563 pubmed
- DERIVEDSylla P, Lam K, Komen N, Tuech JJ, Spinelli A, Martz J, Rhee R, Marcet J, Cadiere GB, Rouanet P, Karachun A, Denost Q, Sametdinov N, D'Hoore A, Lee S, Lefevre JH. Safety and Performance of the Colovac Anastomosis Protection Device. A Pooled Analysis of Prospective Studies Compared With Diverting Loop Ileostomy (SAFE-2025). Ann Surg. 2026 Sep 2. doi: 10.1097/SLA.0000000000007171. Online ahead of print. PMID 42681563
- DERIVEDLefevre JH, Karachun A, Sametdinov N, Raximov O, Rustamov A, Adilkhodjaev A, Yunusov S, Mirzagolib T, Sylla P. Performance and safety of the Colovac 2 colorectal anastomotic protection device: the SafeHeal SAFE-2023 study. Surg Endosc. 2026 May;40(5):4126-4135. doi: 10.1007/s00464-026-12691-y. Epub 2026 Mar 5. PMID 41787083